Optisulin

Skip To Main Content

This platform is for Australian healthcare professionals only

Optisulin^® (insulin glargine 100 U/mL)

*Image is not an actual patient.

Connect with a rep

About Optisulin

Optisulin^® is the same formulation of insulin glargine 100 U/mL as Lantus (insulin glargine), available in the same range of devices.¹

Optisulin^® is indicated for once-daily subcutaneous administration in the treatment of type 1 diabetes mellitus in adults and children and type 2 diabetes mellitus in adults who require insulin for the control of hyperglycaemia.²

Don’t miss these key links

Optisulin^® Product Information Learn more about Diabetes

Need help? Contact a Rep

For specific questions or support for your team, reach out to a Sanofi representative.

Contact my local rep

Featured content

Optisulin Solostar (insulin glargine 100 units/mL) Injection Guide

These instructions are supplied as a guide only. Always read the full instruction leaflet before you use Optisulin SoloStar for the first time. If you have any questions, ask your healthcare professional.

Resources and tools

Resources and tools

Optisulin^® PI

Optisulin Solostar (insulin glargine 100 units/mL) Injection Guide

These instructions are supplied as a guide only. Always read the full instruction leaflet before you use Optisulin SoloStar for the first time. If you have any questions, ask your healthcare professional.

Patient support

Optisulin Solostar (insulin glargine 100 units/mL) Injection Guide

Optisulin Solostar (insulin glargine 100 units/mL) Injection Guide

These instructions are supplied as a guide only. Always read the full instruction leaflet before you use Optisulin SoloStar for the first time. If you have any questions, ask your healthcare professional.

Science and education

Part 1 of 10: What advantages does Toujeo (insulin glargine 300 U/mL) offer over older basal insulins

Part 1 of 10: What advantages does Toujeo (insulin glargine 300 U/mL) offer over older basal insulins

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Part 2 of 10: What outcomes have you observed in patients who have started Toujeo

Part 2 of 10: What outcomes have you observed in patients who have started Toujeo

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Part 3 of 10: What are the benefits of starting insulin naïve patients on a basal insulin instead of a premix or co-formulation insulin

Part 3 of 10: What are the benefits of starting insulin naïve patients on a basal insulin instead of a premix or co-formulation insulin

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Part 4 of 10: Managing post-prandial spikes – basal and premixed insulin

Part 4 of 10: Managing post-prandial spikes – basal and premixed insulin

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Part 5 of 10: The benefits of early combination therapies

Part 5 of 10: The benefits of early combination therapies

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Part 6 of 10: How does GLP-1 complement basal insulin in the management of type 2 diabetes

Part 6 of 10: How does GLP-1 complement basal insulin in the management of type 2 diabetes

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Part 7 of 10: What to expect when using Toujeo (insulin glargine 300 U/mL) plus GLP-1 therapies

Part 7 of 10: What to expect when using Toujeo (insulin glargine 300 U/mL) plus GLP-1 therapies

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Part 8 of 10: Benefits of early combination therapy of GLP-1 and basal

Part 8 of 10: Benefits of early combination therapy of GLP-1 and basal

Join Professor Robert Ritzel in this 10 part series on harnessing the synergies of Basal Insulin and GLP-1 RA Therapies

Can’t find what you’re looking for?
Search our extensive Content Library

Search our Content Library

PBS information:

Optisulin^® SoloStar^® and Optisulin^® cartridges are listed on the PBS as a long acting insulin analogue for the treatment of type 1 diabetes and for adults with type 2 diabetes.

Please review Product Information before prescribing Optisulin^® (insulin glargine 100U/mL). Full Product Information is available at https://medsinfo.com.au/product-information/document/Optisulin_PI or by calling 1800 818 806.

PBS Information:

Toujeo^® Solostar^® is listed on the PBS as a long-acting insulin analogue for the treatment of type 1 and type 2 diabetes in adults and children 6 years and older.

Please review product information before prescribing Toujeo^® (insulin glargine 300U/mL). Full Product Information is available at https://medsinfo.com.au/product-information/document/Toujeo_PI or by calling 1800 818 806.

The Royal Australian College of General Practitioners. Management of type 2 diabetes: A handbook for general practice. East Melbourne, Vic: RACGP, 2020.
Optisulin^® Product Information view at: https://medsinfo.com.au/product-information/document/Optisulin_PI.

MAT-AU-2200652 - 4.0 - 02/2026